康恩貝(600572.SH):金華康恩貝阿莫西林膠囊擬中選全國藥品集中採購
格隆匯1月17日丨康恩貝(600572.SH)公佈,2020年1月17日,公司控股子公司浙江金華康恩貝生物製藥有限公司(以下簡稱“金華康恩貝”)已通過國家藥品監督管理局仿製藥質量和療效一致性評價的阿莫西林膠囊參加了第二批全國藥品集中採購的投標。經聯合採購辦公室開標、評標後,金華康恩貝參與投標藥品擬中標本次集中採購。
根據聯合採購辦公室及有關報道信息,除金華康恩貝外,本次阿莫西林膠囊品種擬中標企業還有中國醫藥健康產業股份有限公司、華北製藥股份有限公司、山東魯抗醫藥股份有限公司等5家公司。
金華康恩貝本次擬中標的產品阿莫西林膠囊,2019年1-9月銷售收入約為831.42萬元,約佔公司2019年1-9月營業收入53.93億元的0.15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.